Loading
ADRA2C (Alpha-2C adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression. Control a variety of physiological processes, such as regulation of blood pressure, lipolysis and insulin release. ADRA2A and ADRA2C mediates the presynaptic feedback inhibition of neurotransmitter release from noradrenergic nerve terminals in sympathetic and central nervous systems. ADRA2A inhibits transmitter release at high stimulation frequencies, whereas ADRA2C modulates neurotransmission at lower levels of nerve activity. The rank order of potency for physiological agonists of ADRA2C is epinephrine > norepinephrine > dopamine. Location: Cell membrane (UniProt). Locus 4p16.3 (HGNC).
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"ADRA2C" OR ABSTRACT:"ADRA2C" OR TITLE:"adrenoceptor alpha 2C" OR ABSTRACT:"adrenoceptor alpha 2C" OR TITLE:"Alpha-2C adrenergic receptor" OR ABSTRACT:"Alpha-2C adrenergic receptor" OR TITLE:"ADRARL2" OR ABSTRACT:"ADRARL2" OR TITLE:"ADRA2L2" OR ABSTRACT:"ADRA2L2" OR TITLE:"ADRA2RL2" OR ABSTRACT:"ADRA2RL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ADRA2C, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/adra2c.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/adra2c.json. Licence CC BY-NC 4.0.